Williams David F
1 Wake Forest Institute of Regenerative Medicine , Winston Salem, North Carolina.
Tissue Eng Part A. 2014 Apr;20(7-8):1129-31. doi: 10.1089/ten.tea.2013.0769. Epub 2014 Feb 14.
The development of biomaterials for use in tissue engineering processes has not so far followed a scientifically valid pathway; there have been no properly constituted specifications for these biomaterials, whose choice has often been dictated by the perceived need to comply with prior FDA approval for use of the materials in nontissue engineering applications. This short essay discusses the difficulties that have resulted in this approach and provides both conceptual and practical solutions for the future, based on sound principles of biocompatibility and the need to use tissue engineering templates that replicate the niche of the target cells.
用于组织工程过程的生物材料的开发迄今为止尚未遵循科学有效的途径；对于这些生物材料，没有适当制定的规范，其选择往往取决于认为需要符合美国食品药品监督管理局（FDA）先前对这些材料在非组织工程应用中的使用批准。这篇短文讨论了导致这种方法的困难，并基于生物相容性的合理原则以及使用复制靶细胞生态位的组织工程模板的必要性，为未来提供了概念性和实用性的解决方案。
